MultiXBa
Prodotto naturale per la salute autorizzato in Canada
- Altri nomi
- MultiX Rectal Powder
- Titolare
- Voyageur Pharmaceuticals Ltd.
- NPN o DIN-HM
- 80109042
- Stato
- Licenza attiva
- Data della licenza
- 31 marzo 2021
- Data di revisione
- Non indicata
- Forma
- Poudre pour suspension
- Via di somministrazione
- Rectale
- Tipo di domanda
- Non traditionnelle
L’analisi delle dosi orali non si applica senza una via esclusivamente orale accertata.
Composizione
| Ingrediente medicinale e fonte | Per unità posologica, secondo la fonte |
|---|---|
| Acide sulfurique, sel de barium (1:1) | 96 % (p/p) |
| Acide sulfurique, sel de barium (1:1) | 480 g |
Ingredienti non medicinali
Poly(sorbate) 80, Sorbitol, NA, Citrate de sodium, Siméthicone, Pectine
Dosi raccomandate in Canada
| Popolazione | Età | Quantità per assunzione | Frequenza |
|---|---|---|---|
Adulti e adolescenti Tradotto automaticamente dal francese. Vedi l’originaleAdultes et adolescents | Traduzione non disponibile. Testo originale, lingua: francese. minimum : 13 ans | Traduzione non disponibile. Testo originale, lingua: francese. 1 Portion(s) | Traduzione non disponibile. Testo originale, lingua: francese. 1 Tous les jours |
Bambini Tradotto automaticamente dal francese. Vedi l’originaleEnfants | Traduzione non disponibile. Testo originale, lingua: francese. minimum : 4 ans ; maximum : 8 ans | Traduzione non disponibile. Testo originale, lingua: francese. 1 Portion(s) | Traduzione non disponibile. Testo originale, lingua: francese. 1 Tous les jours |
Adolescenti Tradotto automaticamente dal francese. Vedi l’originaleAdolescentes | Traduzione non disponibile. Testo originale, lingua: francese. minimum : 9 ans ; maximum : 13 ans | Traduzione non disponibile. Testo originale, lingua: francese. 1 Portion(s) | Traduzione non disponibile. Testo originale, lingua: francese. 1 Tous les jours |
Usi autorizzati in Canada
Traduzione non disponibile. Testo originale, lingua: francese.
For radiographic examination of the gastrointestinal tract. For use as a single or double contrast radiological medium for lower gastrointestinal procedures by conventional X-Ray.Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.
Avvertenze in Canada
Traduzione non disponibile. Testo originale, lingua: francese.
Contre-indications : Known or suspected fistula, perforation or obstruction of the lower gastrointestinal tract, recent rectal biopsy or known hypersensitivity to barium sulfate or any of the non medicinal ingredients.Traduzione non disponibile. Testo originale, lingua: francese.
Précautions et mises en garde : For professional use only. Do not use if the inner seal is broken or missing. Discard any unused reconstituted suspension. Diagnostic procedures that involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be excerised with the use of radiopaque media in severly debilitated patients and in those with marked hypertension or advanced cardiac disease. Ingestion of barium is not recommended in patients with a history of food aspiration. If barium swallow studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. Administer initially small amounts such as a half-teaspoon of low-density barium and carefully observe swallowing under fluoroscopic control. If barium is aspired into the larynx, further administartion of barium should be immediately discontinued. If no aspiration is noted, additional barium may be given with continued fluoroscopic monitoring for aspiration. After any barium study of the G.I. tract, it is important to rehydrate the patient as quickly as possible to prevent impaction of barium. To prevent barium impaction, the colon may also require the use of cathartics following the completion of the examination. Saline cathartics are recommended on a routine basis and especially in patients with a history of constipation unless clinically contraindicated. Where enema tips are used, care must be taken during insertion into the patient, since forceful or too deep insertion may cause tearing or perforation of the rectum. When balloon retention tips are used, care should be given taken to avoid over-inflation of the balloon, since overfilling or asymmetrical filling with displacement of the tip may occur. Such a displacement can lead to rectal perforation or barium granulomas. Inflation of the balloon should be done under fluroscopic control by qualified professional personnel. Usage in Pregnancy: Radiation is known to cause harm to the unborn fetus exposed in utero. Therefore, radiographic procedures should only be used when, in the judgement of the physician, its use is deemed essential to the welfare of the pregnant patient. Safe use of barium sulfate in pregnant is not established.Traduzione non disponibile. Testo originale, lingua: francese.
Effets indésirables connus : Rarely, severe allergic reactions of an anaphylactoid nature, have been reported following administration of barium sulfate contrast agents. Adverse reaction accompanying the use of barium sulfate formulations are infrequent and usually mild, though severe reactions (approximately 1 in 500,000) and fatalities (approximately 1 in 2,000,000) have occurred. Procedural complications are rare, but may include aspiration pneueumonitis, barium impaction, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities. EKG changes have been shown to occur following or during barium enemas. It is of the utmost importance to be completely prepared to treat any such occurrence. Allergic reactions: Due to the increased likelyhood of allergic reactions in atopic patients, it is important that a complete history of known and suspected allergies as well as allergic-like symptoms, e.g. rhinitis, bronchial asthma, eczema and uticarial, be obtained prior to any medical procedure utilizing the products. A mild allergic reaction would most likely include generalized pruritus, erythema or urticaria (approximately 1 in 100,000 reactions). Such reaction will generally respond to antihistamine such as 50 mg of diphenhydramine or its equivalent. In the rarer, more serious reactions (approximately 1 in 500,000) laryneal edema, brochospasm or hypotension could develop. Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, or hypotension, reflex tachycardia, dyspnea, agitation, confusion and cyanosis, progressing to unconsciousness. Treatment should be initiated immediately with 0.3 - 0.5 cc of 1:000 epinephrine subcutaneously. If brochospasm predominates, 0.25 - 0.50 gram of intravenous aminophylline should be given slowly. Appropriate vasopressors might be required. Adrenocorticosteroids, even if given intravenously, exert no significant effect on the acute allergic reaction for a few hours. The administration of thesesteroid agents should not be reagrded as emergency measures for the treatment of allergic reactions. Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following administration of any diagnostic agent. Such reactions are usually non allergenic in nature and best treated by having the patient lie flat for an additional 10 to 30 minutes under observation. However, allergic reactions to the enema accessories, in particular to retention catheters (tips) with latex cuffs, can occur. Such reactions could occur immediately and result in the previous mentionedacute allergic-like responses or might be delayed in appearance and result in a contact dermatitis. Known atopic patients particularly those with a history of asthma or eczema should be evaluated for the alternative methods of administration in order to avoid these adverse reactions. All plastic/rubber accessories are disposable, single use devices that must not be reused or left in the body cavity for an extended period of time. In rare occassions following repeated administration, severe stomach cramps and diarrhea may occur. These are transitory in nature and are not considered serious.Fonte
Scheda ufficiale Health Canada, licenza 80109042
Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.
Contient des informations visées par la Licence du gouvernement ouvert – Canada (Santé Canada, BDPSNH)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.
La data della prova di questo elenco di ingredienti è sconosciuta.
Il prodotto è cambiato? Fotografi la confezione.